Русский
Ambroxol in the treatment of acute bronchitis and COVID-19
DOI: https://dx.doi.org/10.18565/therapy.2022.6.151-156
Alieva A.M., Batov M.A., Karabinenko A.A.
1) N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, Moscow; 2) P.A. Herzen Moscow Scientific And Research Oncological Institute of Oncology – a branch of National Medical Research Radiological Centre of the Ministry of Healthcare of Russia
Literature
1. Zhou P., Yang X.L., Wang X.G. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798): 270–73. https://dx.doi.org/10.1038/s41586-020-2012-7. 2. Yelin D., Wirtheim E., Vetter P. et al. Long-term consequences of COVID-19: Research needs. Lancet Infect Dis. 2020; 20(10): 1115 –17. https://dx.doi.org/10.1016/S1473-3099(20)30701-5. 3. Blackwell D.L., Lucas J.W., Clarke T.C. Summary health statistics for U.S. adults: national health interview survey, 2012. Vital Health Stat 10. 2014; 260: 1–161. 4. Леонов С.А., Сон И.М., Моравская С.В. Динамика заболеваемости с временной утратой трудоспособности в Российской Федерации в 2007–2011 годах. Менеджер здравоохранения. 2013; 8: 6–14. [Leonov S.А., Son I.M., Moravskaya S.V. Dynamics of morbidity with a temporary disability in Russian Federation in the period of 200 –2011 years. Menedzher zdravookhraneniya = Healthcare Manager. 2013; 8: 6–14 (In Russ.)]. EDN: RBTBKB. 5. Лебедева-Несевря Н.А., Костарев В.Г., Никифорова Н.В., Цинкер М.Ю. Заболеваемость с временной утратой трудоспособности работающего населения: федеральные и региональные показатели и тенденции 2005–2014 гг. Гигиена и санитария. 2017; 96(11): 1054–1059. [Lebedeva-Nesevrya N.A., Kostarev V.G., Nikiforova N.V., Tsinker M.Yu. Morbidity with temporary loss of work capacity in working population: federal and regional indices and trends over 2005–2014. Gigiena i sanitariya = Hygiene and Sanitation Russian Journal. 2017; 96(11): 1054–1059 (In Russ.)]. https://dx.doi.org/10.18821/0016-9900-2017-96-11-1054-1059. EDN: YOBWVJ. 6. Harris A.M., Hicks L.A., Qaseem A.; High value care task force of the American College of Physicians and for the Centers for Disease Control and Prevention. Appropriate antibiotic use for acute respiratory tract infection in adults: Advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2016; 164(6): 425–34.https://dx.doi.org/10.7326/M15-1840. 7. Wenzel R.P., Fowler A.A. 3rd. Clinical practice. Acute bronchitis. N Engl J Med. 2006; 355(20): 2125–30.https://dx.doi.org/10.1056/NEJMcp061493. 8. Jonsson J.S., Sigurdsson J.A., Kristinsson K.G. et al. Acute bronchitis in adults. How close do we come to its aetiology in general practice? Scand J Prim Health Care. 1997; 15(3): 156–60. https://dx.doi.org/10.3109/02813439709018507. 9. Creer D.D., Dilworth J.P., Gillespie S.H. et al. Aetiological role of viral and bacterial infections in acute adult lower respiratory tract infection (LRTI) in primary care. Thorax. 2006; 61(1): 75–79. https://dx.doi.org/10.1136/thx.2004.027441. 10. Bai L., Su X., Zhao D. et al. Exposure to traffic-related air pollution and acute bronchitis in children: Season and age as modifiers. J Epidemiol Community Health. 2018; 72(5): 426–33. https://dx.doi.org/10.1136/jech-2017-209948. 11. Saust L.T., Bjerrum L., Siersma V. et al. Quality assessment in general practice: diagnosis and antibiotic treatment of acute respiratory tract infections. Scand J Prim Health Care. 2018; 36(4): 372–79. https://dx.doi.org/10.1080/02813432.2018.1523996. 12. Kinkade S., Long N.A. Acute bronchitis. Am Fam Physician. 2016; 94(7): 560–65. 13. 1Jonsson J.S., Gíslason T., Gíslason D., Sigurdsson J.A. Acute bronchitis and clinical outcome three years later: Prospective cohort study. BMJ. 1998; 317(7170): 1433. https://dx.doi.org/10.1136/bmj.317.7170.1433. 14. Braman S.S. Chronic cough due to acute bronchitis: ACCP evidence-based clinical practice guidelines. Chest. 2006; 129(1 Suppl): 95S–103S. https://dx.doi.org/10.1378/chest.129.1_suppl.95S. 15. Ebell M.H., Lundgren J., Youngpairoj S. How long does a cough last? Comparing patients’ expectations with data from a systematic review of the literature. Ann Fam Med. 2013; 11(1): 5–13. https://dx.doi.org/10.1370/afm.1430. 16. Schroeder K., Fahey T. Should we advise parents to administer over the counter cough medicines for acute cough? Systematic review of randomised controlled trials. Arch Dis Child 2002; 86(3): 170–75. https://dx.doi.org/10.1136/adc.86.3.170. 17. European Medicine Agency. Revised assessment report: Ambroxol and bromhexine containing medicinal product. 10 September 2015. URL: https://www.ema.europa.eu/en/documents/referral/ambroxol-bromhexine-article-31-referral-prac-assessment-report_en.pdf (date of access – 01.08.2022). 18. Cazan D., Klimek L., Sperl A. et al. Safety of ambroxol in the treatment of airway diseases in adult patients. Expert Opin Drug Saf. 2018; 17(12): 1211–24. https://dx.doi.org/10.1080/14740338.2018.1533954. 19. Zanasi A., Mazzolini M., Kantar A. A reappraisal of the mucoactive activity and clinical efficacy of bromhexine. Multidisci Respir Med. 2017; 12: 7. https://dx.doi.org/10.1186/s40248-017-0088-1. 20. Yang B., Yao D.F., Ohuchi M. et al. Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels. Eur Respir J. 2002; 19(5): 952–58. https://dx.doi.org/10.1183/09031936.02.00253302. 21. Gupta P.R. Ambroxol – resurgence of an old molecule as an anti-inflammatory agent in chronic obstructive airway diseases. Lung India. 2010; 27(2): 46–48. https://dx.doi.org/10.4103/0970-2113.63603. 22. Muroi Y., Undem B.J. Targeting voltage gated sodium channels NaV1.7, Na V1.8, and Na V1.9 for treatment of pathological cough. Lung. 2014; 192(1): 15–20. https://dx.doi.org/10.1007/s00408-013-9533-x. 23. Li F., Yu J., Yang H. et al. Effects of ambroxol on alginate of mature Pseudomonas aeruginosa biofilms. Curr Microbiol. 2008; 57(1): 1–7. https://dx.doi.org/10.1007/s00284-008-9142-8. 24. Deretic V., Timmins G.S. Enhancement of lung levels of antibiotics by ambroxol and bromhexine. Expert Opin Drug Metab Toxicol .2019; 15(3): 213–18. https://dx.doi.org/10.1080/17425255.2019.1578748. 25. Matthys H., de Mey C., Carls C. et al. Efficacy and tolerability of myrtol standardized in acute bronchitis. A multi-centre, randomised, double-blind, placebo-controlled parallel group clinical trial vs. cefuroxime and ambroxol. Arzneimittelforschung. 2000; 50(8): 700–11. https://dx.doi.org/10.1055/s-0031-1300276. 26. Schulz M., Hammerlein A., Hinkel U. et al. Safety and usage pattern of an over-the-counter ambroxol cough syrup: A community pharmacy-based cohort study. Int J Clin Pharmacol Ther. 2006; 44(9): 409–21. https://dx.doi.org/10.5414/cpp44409. 27. Kardos P., Beeh K.M., Sent U. et al. Characterization of differential patient profiles and therapeutic responses of pharmacy customers for four ambroxol formulations. BMC Pharmacol Toxicol. 2018; 19(1): 40. https://dx.doi.org/10.1186/s40360-018-0229-y. 28. Kumar P. Co-aerosolized pulmonary surfactant and ambroxol for COVID-19 ARDS Intervention: What are we waiting for? Front Bioeng Biotechnol. 2020; 8: 577172. https://dx.doi.org/10.3389/fbioe.2020.577172. 29. Bocci G., Bradfute S.B., Ye C. et al. Virtual and in vitro antiviral screening revive therapeutic drugs for COVID-19. ACS Pharmacol Transl Sci. 2020; 3(6): 1278–92. https://dx.doi.org/10.1021/acsptsci.0c00131. 30. Bradfute S.B., Ye C., Clarke E.C. et al. Ambroxol and ciprofloxacin show activity against SARS-CoV2 in Vero E6 cells at clinically-relevant concentrations. bioRxiv. 2020; 2020.08.11.245100. https://dx.doi.org/10.1101/2020.08.11.245100. Preprint. 31. Olaleye O.A., Kaur M., Onyenaka C.C. Ambroxol hydrochloride inhibits the interaction between severe acute respiratory syndrome coronavirus 2 spike protein’s receptor binding domain and recombinant human ACE2. bioRxiv. 2020; 2020.09.13.295691.https://dx.doi.org/10.1101/2020.09.13.295691. Preprint. 32. Carpinteiro A., Gripp B., Hoffmann M. et al. Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells. J Biol Chem. 2021; 296: 100701. https://dx.doi.org/10.1016/j.jbc.2021.100701.
About the Autors
Amina M. Alieva, PhD in Medicine, associate professor of the Department of hospital therapy No. 2 of the Faculty of general medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 117997, Moscow, 1 Ostrovityanova Str. E-mail: amisha_alieva@mail.ru. ORCID: https://orcid.org/0000-0001-5416-8579. SPIN-code: 2749-6427
Maxim A. Batov, resident doctor at P.A. Herzen Moscow Scientific and Research Oncological Institute of Oncology – a branch of National Medical Research Radiological Centre of the Ministry of Healthcare of Russia. Address: 125284, Moscow, 3 2nd Botkinsky Lane. E-mail: m.batov112@gmail.com. ORCID: https://orcid.org/0000-0002-3780-4358. SPIN-code: 5850-7711
Alexander A. Karabinenko, Dr. med. habil., professor of the Department of hospital therapy No. 2 of the Faculty of general medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, therapist and pulmonologist of the highest category. Address: 117997, Moscow, 1 Ostrovityanova Str.
Similar Articles
